Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA.
J Card Fail. 2009 Dec;15(10):819-27. doi: 10.1016/j.cardfail.2009.07.004. Epub 2009 Aug 21.
The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial revealed no significant differences among 1587 symptomatic heart failure patients randomized to warfarin, clopidogrel, or aspirin in time to all-cause death, nonfatal myocardial infarction, or nonfatal stroke. We compared within-trial medical resource use and costs between treatments.
We assigned country-specific costs to medical resources incurred during follow-up. Annualized rates of hospitalizations, inpatient and outpatient procedures, and emergency department visits did not differ significantly between groups. Annualized total costs averaged $5901 (95% confidence interval [CI], $4776-$7520) for the aspirin group, $5646 (95% CI, $4903-$6584) for the clopidogrel group, and $5830 (95% CI, $4838-$7400) for the warfarin group.
Consistent with clinical findings, our analyses did not identify significant cost differences between treatments.
华法林和抗血小板治疗慢性心力衰竭（WATCH）试验显示，1587 例有症状的心力衰竭患者随机分为华法林、氯吡格雷或阿司匹林组，在全因死亡、非致死性心肌梗死或非致死性卒中方面无显著差异。我们比较了治疗组之间的试验内医疗资源使用和成本。
我们为随访期间发生的医疗资源分配了特定国家的成本。各组的住院、住院和门诊程序以及急诊就诊的年化率无显著差异。阿司匹林组的年化总成本平均为 5901 美元（95%置信区间 [CI]，4776-7520 美元），氯吡格雷组为 5646 美元（95% CI，4903-6584 美元），华法林组为 5830 美元（95% CI，4838-7400 美元）。
与临床发现一致，我们的分析并未发现治疗之间存在显著的成本差异。
